PReMA is delighted to announce that Dr. Kengkran Louvirojanakul has been appointed as Chief Executive Officer, effective March 2022.
Dr. Kengkran previously served as a spokesperson and Head of Public Affairs at Grab from 2019 to 2022. His outstanding achievements in the management and shaping policy on ride-hailing and transport, food delivery, and last mile logistics earned him the 2021 CEO’s Award. Prior to joining Grab, he served as Director of Corporate Affairs and Communications at JTI, where he acquired experience in high-level government agencies partnership and engagements to resolve policy and regulatory issues, that resulted in more business-conducive environments.
Earlier in his career, Dr. Kengkran served close to a decade as a Thai Diplomat on Ministry of Foreign Affairs (MoFA) international assignments in Thailand, India, and China. During this period, he was also a recipient of a MoFA scholarship to pursue his doctorate degree in law, completing his formal legal training.
To this new role, Dr. Kengkran brings diverse and unique experiences from both the public and private sectors, where he has been integral in shaping businesses’ public and government affairs strategies and moving past regulatory obstacles, which we believe will be valuable for our association. In his new role at PReMA, he will serve as the keystone of membership relations and the team’s leader, engaging directly with members to better understand their needs for a greater involvement and inclusion, as well as PReMA colleagues to devise strategies and identify the actions needed to drive Association’s and members’ collective initiatives forward.
With Dr. Kengkran’s vision and almost two-decade’s expertise in government affairs along with his leadership in building a highly productive and successful teams in JTI and Grab, we are confident that he will be successful in reinforcing our commitment to promoting the value of innovation, expanding access to innovative medicines, and empowering patients, as well as continuing to raise the bar and drive PReMA’s vision as we emerge through the pandemic.
We hope you will join us in congratulating Dr. Kengkran on his new appointment as well as welcoming him to PReMA.
Let’s learn more about drug classes
Apart from scientific problems encountered during R&D, another drug challenge is varying classes of medicines, e.g. small molecules, biotherapeutics, and vaccines are usually characterised by systemic scientific challenges. Solutions for one drug class may not be applicable for other drug classes that the technological focus is fundamentally different.